Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity
- 14 September 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 138 (38) , 12494-12501
Abstract
Single-nanoparticle (NP) combination chemotherapeutics are quickly emerging as attractive alternatives to traditional chemotherapy due to their ability to increase drug solubility, reduce off-target toxicity, enhance blood circulation lifetime, and increase the amount of drug delivered to tumors. In the case of NP-bound drugs, that is, NP-prodrugs, the current standard of practice is to assume that the subcellular mechanism of action for each drug released from the NP mirrors that of the unbound, free-drug. Here, we use an RNAi signature assay for the first time to examine the mechanism of action of multidrug-conjugated NP prodrugs relative to their small molecule prodrugs and native drug mechanisms of action. Additionally, the effective additive contribution of three different drugs in a single-NP platform is characterized. The results indicate that some platinum(IV) cisplatin prodrugs, although cytotoxic, may not have the expected mechanism of action for cisplatin. This insight was utilized to develop a novel platinum(IV) oxaliplatin prodrug and incorporate it into a three-drug-conjugated NP, where each drug’s mechanism of action is preserved, to treat tumor-bearing mice with otherwise lethal levels of chemotherapy.Keywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (1R21EB018529-01A1)
- Ludwig Institute for Cancer Research
- Life Sciences Research Foundation
- National Science Foundation
This publication has 67 references indexed in Scilit:
- Defining principles of combination drug mechanisms of actionProceedings of the National Academy of Sciences, 2012
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling NetworksCell, 2012
- Synthesis, Characterization, and Cytotoxicity of Platinum(IV) Carbamate ComplexesInorganic Chemistry, 2011
- A mammalian functional-genetic approach to characterizing cancer therapeuticsNature Chemical Biology, 2010
- Core-Clickable PEG-Branch-Azide Bivalent-Bottle-Brush Polymers by ROMP: Grafting-Through and Clicking-ToJournal of the American Chemical Society, 2010
- Drug-Loaded, Bivalent-Bottle-Brush Polymers by Graft-through ROMPMacromolecules, 2010
- Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapyProceedings of the National Academy of Sciences, 2010
- Photoregulated Release of Caged Anticancer Drugs from Gold NanoparticlesJournal of the American Chemical Society, 2009
- Topoisomerase levels determine chemotherapy response in vitro and in vivoProceedings of the National Academy of Sciences, 2008